On August 23, 2021 EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and Manhattan BioSolutions, an emerging biotechnology company developing immunoregulatory therapies for the treatment of metastatic cancers, repored that they have been awarded a grant from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) program (Press release, Manhattan BioSolutions, AUG 23, 2021, View Source [SID1234586954]). The UB CAT grant will enable the pharmacological assessment of novel computationally-designed biologic agents for the treatment of immune-mediated and viral diseases. This collaborative research will be conducted in partnership with the laboratory of Dr. Dhaval Shah, an Associate Professor at the Department of Pharmaceutical Sciences, University at Buffalo, whose cutting-edge research in protein therapeutics and pharmacokinetic-pharmacodynamic modeling has significantly impacted the drug development field around the globe.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The proposed project is based on the novel evolution-based, artificial intelligence (AI)-enabled antibody discovery platform developed by EVQLV. The in silico designed fully human antibody candidates against preselected targets will be tested experimentally for pharmacological effects in preclinical models to further demonstrate the utility of the EVQLV’s AI engine to deep-mine vast amounts of massive sequencing and structural databases to guide therapeutic antibody discovery and development.
Andrew Satz, Chief Executive Officer of EVQLV, commented: "Through our collaboration, we will continue to demonstrate how AI and machine learning can guide therapeutic antibody discovery and development. We strongly believe that generating and testing biologics, in the computer, prior to proceeding into biologic systems can accelerate how medicines reach patients in need".
Dr. Boris Shor, Chief Executive Officer, Manhattan BioSolutions, commented, "We are pleased to collaborate with EVQLV and Dr. Shah’s laboratory at the University at Buffalo. Our efforts will augment Manhattan BioSolutions’ current discovery plans aimed at the development of unique monoclonal antibodies targeting immunoregulatory receptors implicated in both cancer and inflammation".
Dr. Dhaval Shah commented: "The primary benefit of this collaboration is the strong synergy between our teams based on the unique expertise in computational science, translational pharmacology, and pharmacokinetic modeling of novel biologics. Together, we will be in a strong position to fully validate the computationally designed antibodies in preclinical experiments."